RBC Capital analyst Simos Simeonidis lowered his price target on Zafgen (NASDAQ: ZFGN) to $20.00 (from $46.00) but maintained an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change FDA

Zafgen (ZFGN) Looks for Higher Open Following Volatile Trading WeekOctober 19, 2015 9:15 AM UPDATE: FBR Downgrades Zafgen (ZFGN) to Sector PerformOctober 16, 2015 2:56 PM Cowen Cuts Price Target on Zafgen (ZFGN) as Beloranib is Placed on Hold Following Patient Death October 16, 2015 1:28 PM Zafgen (ZFGN) PT Cut to $46 at Leerink Partners Amid Partial Clinical Hold; Maintains Bullish ViewOctober 16, 2015 12:07 PM Zafgen's (ZFGN) Beloranib Placed on Partial Clinical Hold by FDAOctober 16, 2015 6:31 AM Zafgen Announces Partial Clinical Hold Affecting Beloranib TrialsOctober 16, 2015 6:30 AM